Dupliumab therapy for alopecia areata: a case series and review of the literature

References

• Dainichi T, Iwata M, Kaku Y. Alopecia areata: what’s new in the epidemiology, comorbidities, and pathogenesis? J Dermatol Sci. 2023;112(3):1–11. doi: 10.1016/j.jdermsci.2023.09.008. From NLM.
   Web of Science ®Google Scholar
• Muntyanu A, Gabrielli S, Donovan J, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. 2023;37(8):1490–1520. From NLM. doi: 10.1111/jdv.18926.
   Web of Science ®Google Scholar
• Lauron S, Plasse C, Vaysset M, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(3):281–288. From NLM. doi: 10.1001/jamadermatol.2022.6085.
   PubMed Web of Science ®Google Scholar
• Lintzeri DA, Constantinou A, Hillmann K, et al. Alopecia areata - Current understanding and management. J Dtsch Dermatol Ges. 2022;20(1):59–90. From NLM. doi: 10.1111/ddg.14689.
   Web of Science ®Google Scholar
• Tosti A. Alopecia areata: the clinician and patient voice. J Drugs Dermatol. 2023;22(10):967–975. From NLM. doi: 10.36849/jdd.Sf396143.
   PubMedGoogle Scholar
• Liu M, Gao Y, Yuan Y, et al. Janus kinase inhibitors for alopecia areata: a systematic review and Meta-Analysis. JAMA Netw Open. 2023;6(6):e2320351. From NLM. doi: 10.1001/jamanetworkopen.2023.20351.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Linsell L, Johansson E, et al. Treatments for moderate-to-severe alopecia areata: a systematic narrative review. Dermatol Ther (Heidelb). 2023;13(12):2951–2991. From NLM. doi: 10.1007/s13555-023-01044-5.
   PubMed Web of Science ®Google Scholar
• Yan D, Fan H, Chen M, et al. The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies. Front Pharmacol. 2022;13:950450. From NLM. doi: 10.3389/fphar.2022.950450.
   PubMedGoogle Scholar
• Huang J, Deng S, Li J, et al. Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: a retrospective study. Acta Derm Venereol. 2023;103:adv13475. From NLM. doi: 10.2340/actadv.v103.13475.
   PubMed Web of Science ®Google Scholar
• Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021;21(2):215–230. From NLM. doi: 10.1007/s10238-020-00673-w.
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Pavel AB, Del Duca E, et al. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy. 2023;78(4):1047–1059. From NLM. doi: 10.1111/all.15561.
   PubMed Web of Science ®Google Scholar
• Chen W, Li S, Cai X, et al. Association between alopecia areata and atopic dermatitis: current evidence. J Eur Acad Dermatol Venereol. 2023;37(8):1447–1673, e945–e1088. doi: 10.1111/jdv.19044.
   Web of Science ®Google Scholar
• Zeng Z, Li S, Ye Y, et al. Allergen desensitization reduces the severity of relapsed alopecia areata in dust-mite allergic patients. Exp Dermatol. 2023;32(7):1108–1119. From NLM. doi: 10.1111/exd.14819.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Renert-Yuval Y, Bares J, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients. Allergy. 2022;77(3):897–906. From NLM. doi: 10.1111/all.15071.
   PubMed Web of Science ®Google Scholar
• Marks DH, Mesinkovska N, Senna MM. Cause or cure? Review of dupilumab and alopecia areata. J Am Acad Dermatol. 2023;88(3):651–653. From NLM. doi: 10.1016/j.jaad.2019.06.010.
   PubMedGoogle Scholar
• Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;10356;400(10356):908–919. doi: 10.1016/s0140-6736(22)01539-2.From NLM.
   PubMed Web of Science ®Google Scholar
• Xu Y, Guo L, Li Z, et al. Efficacy and safety profile of dupilumab for the treatment of atopic dermatitis in children and adolescents: a systematic review and meta-analysis. Pediatr Dermatol. 2023;40(5):841–850. From NLM. doi: 10.1111/pde.15398.
   PubMedGoogle Scholar
• Chun PIF, Lehman H. Current and future monoclonal antibodies in the treatment of atopic dermatitis. Clin Rev Allergy Immunol. 2020;59(2):208–219. From NLM. doi: 10.1007/s12016-020-08802-9.
   PubMed Web of Science ®Google Scholar
• Spekhorst LS, Bakker D, Drylewicz J, et al. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy. 2022;77(11):3398–3407. From NLM. doi: 10.1111/all.15439.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56. From NLM. doi: 10.1001/jamadermatol.2019.3336.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293. From NLM. doi: 10.1016/j.jaad.2020.06.054.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Roberts J, Sperling L, et al. Objective outcome measures: collecting meaningful data on alopecia areata. J Am Acad Dermatol. 2018;79(3):470–478.e3. e473 From NLM. doi: 10.1016/j.jaad.2017.10.048.
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Kitchen H, Knight S, et al. Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. Am J Clin Dermatol. 2020;21(5):725–732. From NLM. doi: 10.1007/s40257-020-00545-9.
   PubMed Web of Science ®Google Scholar
• Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an Open-Label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393–408. From NLM. doi: 10.1007/s40257-022-00685-0.
   PubMed Web of Science ®Google Scholar
• Darrigade AS, Legrand A, Andreu N, et al. Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. Br J Dermatol. 2018;179(2):534–536. From NLM. doi: 10.1111/bjd.16711.
   PubMed Web of Science ®Google Scholar
• Penzi LR, Yasuda M, Manatis-Lornell A, et al. Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. JAMA Dermatol. 2018;154(11):1358–1360. From NLM. doi: 10.1001/jamadermatol.2018.2976.
   PubMed Web of Science ®Google Scholar
• Uchida H, Kamata M, Watanabe A, et al. Dupilumab improved alopecia areata in a patient with atopic dermatitis: a case report. Acta Derm Venereol. 2019;99(7):675–676. From NLM. doi: 10.2340/00015555-3183.
   PubMed Web of Science ®Google Scholar
• Smogorzewski J, Sierro T, Compoginis G, et al. Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep. 2019;5(2):116–117. From NLM. doi: 10.1016/j.jdcr.2018.11.007.
   PubMedGoogle Scholar
• Alniemi DT, McGevna L. Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis. JAAD Case Rep. 2019;5(2):111–112. From NLM. doi: 10.1016/j.jdcr.2018.11.006.
   PubMedGoogle Scholar
• Patruno C, Napolitano M, Ferrillo M, et al. Dupilumab and alopecia: a janus effect. Dermatol Ther. 2019;32(5):e13023. From NLM. doi: 10.1111/dth.13023.
   PubMed Web of Science ®Google Scholar
• Ludriksone L, Elsner P, Schliemann S. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients. J Dtsch Dermatol Ges. 2019;17(12):1278–1280. From NLM. doi: 10.1111/ddg.13990.
   Web of Science ®Google Scholar
• Call JE, Sahni S, Zug KA. Effectiveness of dupilumab in the treatment of both atopic dermatitis and alopecia universalis. Clin Case Rep. 2020;8(8):1337–1339. From NLM. doi: 10.1002/ccr3.2915.
   PubMed Web of Science ®Google Scholar
• Ushida M, Ohshita A, Arakawa Y, et al. Dupilumab therapy rapidly improved alopecia areata associated with trichotillomania in an atopic dermatitis patient. Allergol Int. 2020;69(3):480–482. From NLM. doi: 10.1016/j.alit.2020.02.009.
   PubMed Web of Science ®Google Scholar
• Magdaleno-Tapial J, Valenzuela-Oñate C, García-Legaz-Martínez M, et al. Improvement of alopecia areata with dupilumab in a patient with severe atopic dermatitis and review the literature. Australas J Dermatol. 2020;61(2):e223–e225. From NLM. doi: 10.1111/ajd.13208.
   PubMed Web of Science ®Google Scholar
• Harada K, Irisawa R, Ito T, et al. The effectiveness of dupilumab in patients with alopecia areata who have atopic dermatitis: a case series of seven patients. Br J Dermatol. 2020;183(2):396–397. From NLM. doi: 10.1111/bjd.18976.
   PubMed Web of Science ®Google Scholar
• Zhu GA, Kang KJW, Chen JK, et al. Inflammatory alopecia in patients on dupilumab: a retrospective cohort study at an academic institution. J Eur Acad Dermatol Venereol. 2020;34(4):e159–e161. From NLM. doi: 10.1111/jdv.16094.
   PubMed Web of Science ®Google Scholar
• Babino G, Fulgione E, D’Ambra I, et al. Rapid hair regrowth induced by dupilumab in a patient affected by alopecia totalis of 28 years’ duration: clinical and dermoscopic features. Dermatol Ther. 2020;33(4):e13582. From NLM. doi: 10.1111/dth.13582.
   PubMed Web of Science ®Google Scholar
• Gruenstein D, Malik K, Levitt J. Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab. JAAD Case Rep. 2020;6(12):1286–1287. From NLM. doi: 10.1016/j.jdcr.2020.10.010.
   PubMedGoogle Scholar
• Szekely S, Vaccari D, Salmaso R, et al. Onset of schamberg disease and resolution of alopecia areata during treatment of atopic dermatitis with dupilumab. J Investig Allergol Clin Immunol. 2021;31(1):65–66. From NLM. doi: 10.18176/jiaci.0541.
   PubMed Web of Science ®Google Scholar
• Muto J, Yoshida S, Doi C, et al. Dupilumab treatment of atopic dermatitis leading to successful treatment of alopecia universalis: a Japanese case report. J Dermatol. 2021;48(2):e72–e73. From NLM. doi: 10.1111/1346-8138.15631.
   PubMed Web of Science ®Google Scholar
• McKenzie PL, Castelo-Soccio L. Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis. J Am Acad Dermatol. 2021;84(6):1691–1694. From NLM. doi: 10.1016/j.jaad.2021.01.046.
   PubMed Web of Science ®Google Scholar
• Abercrombie M, Aleshaki J, Fivenson D. Ophiasis treated with dupilumab. JAAD Case Rep. 2021;16:1–4. From NLM. doi: 10.1016/j.jdcr.2021.07.029.
   PubMedGoogle Scholar
• Choe S, Newman EM. Time to loss of response for dupilumab in ophiasis-pattern alopecia areata. JAAD Case Rep. 2021;15:133–136. From NLM. doi: 10.1016/j.jdcr.2021.07.025.
   PubMedGoogle Scholar
• Alotaibi L, Alfawzan A, Alharthi R, et al. Improvement of atopic dermatitis and alopecia universalis with dupilumab. Dermatol Reports. 2022;14(2):9359. From NLM. doi: 10.4081/dr.2022.9359.
   PubMed Web of Science ®Google Scholar
• Cho SK, Craiglow BG. Dupilumab for the treatment of alopecia areata in children with atopic dermatitis. JAAD Case Rep. 2021;16:82–85. From NLM. doi: 10.1016/j.jdcr.2021.07.015.
   PubMedGoogle Scholar
• Romagnuolo M, Barbareschi M, Tavecchio S, et al. Remission of alopecia universalis after 1 year of treatment with dupilumab in a patient with severe atopic dermatitis. Skin Appendage Disord. 2022;8(1):38–41. From NLM. doi: 10.1159/000517832.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Cantelli M, Potestio L, et al. Clinical, trichoscopic and in vivo reflectance confocal microscopy evaluation of alopecia areata in atopic dermatitis patients treated with dupilumab. J Eur Acad Dermatol Venereol. 2022;36(7):e561–e563. From NLM. doi: 10.1111/jdv.18029.
   PubMed Web of Science ®Google Scholar
• McFeely O, Blasco MC, Doyle C, et al. I feel like a new woman’: atopic dermatitis and alopecia areata treated successfully by dupilumab. Clin Exp Dermatol. 2023;48(3):266–267. From NLM. doi: 10.1093/ced/llac088.
   PubMed Web of Science ®Google Scholar
• Visconti MJ, Richardson A, LaFond AA. Dupilumab as a therapeutic approach in alopecia universalis. Cutis. 2022;110(5):E7–e8. From NLM. doi: 10.12788/cutis.0659.
   PubMed Web of Science ®Google Scholar
• Seo T, Izumi K, Kawamura T, et al. A case of atopic dermatitis-associated dupilumab-resistant alopecia totalis successfully treated with baricitinib. Dermatol Ther. 2022;35(12):e15953. From NLM. doi: 10.1111/dth.15953.
   PubMed Web of Science ®Google Scholar
• Kulkarni M, Rohan CA, Travers JB, et al. Long-Term efficacy of dupilumab in alopecia areata. Am J Case Rep. 2022;23:e936488. From NLM. doi: 10.12659/ajcr.936488.
   PubMed Web of Science ®Google Scholar
• Yan X, Tayier M, Cheang ST, et al. Hair repigmentation and regrowth in a dupilumab-treated paediatric patient with alopecia areata and atopic dermatitis: a case report. Ther Adv Chronic Dis. 2023;14:20406223231191049. From NLM. doi: 10.1177/20406223231191049.
   Web of Science ®Google Scholar
• Cai L, Wei Y, Zhao M, et al. Case report: dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib. Front Med (Lausanne). 2023;10:1253795. From NLM. doi: 10.3389/fmed.2023.1253795.
   PubMed Web of Science ®Google Scholar
• Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. 2018;4(2):143–144. From NLM. doi: 10.1016/j.jdcr.2017.11.020.
   PubMedGoogle Scholar
• Flanagan K, Sperling L, Lin J. Drug-induced alopecia after dupilumab therapy. JAAD Case Rep. 2019;5(1):54–56. From NLM. doi: 10.1016/j.jdcr.2018.10.010.
   PubMedGoogle Scholar
• Barroso-García B, Rial MJ, Molina A, et al. Alopecia areata in severe atopic dermatitis treated with dupilumab. J Investig Allergol Clin Immunol. 2018;28(6):420–421. From NLM. doi: 10.18176/jiaci.0301.
   PubMed Web of Science ®Google Scholar
• Kanda N, Koto M, Hoashi T, et al. Case of alopecia areata during dupilumab treatment for atopic dermatitis. J Dermatol. 2019;46(9):e332–e333. From NLM. doi: 10.1111/1346-8138.14880.
   PubMed Web of Science ®Google Scholar
• Yazdanyar S, Jemec GBE. Alopecia areata after treatment with dupilumab. Dermatitis. 2019;30(2):175–176. From NLM. doi: 10.1097/der.0000000000000458.
   PubMed Web of Science ®Google Scholar
• Salgüero-Fernández I, Gonzalez de Domingo MA, Suarez D, et al. Dermatitis and alopecia in a patient treated with dupilumab: a new adverse effect? Clin Exp Dermatol. 2019;44(3):e41–e43. From NLM. doi: 10.1111/ced.13858.
   PubMed Web of Science ®Google Scholar
• Chung J, Slaught CL, Simpson EL. Alopecia areata in 2 patients treated with dupilumab: new onset and worsening. JAAD Case Rep. 2019;5(8):643–645. From NLM. doi: 10.1016/j.jdcr.2019.03.019.
   PubMedGoogle Scholar
• Barbarin C, Hosteing S, Nosbaum A, et al. Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis. Eur J Dermatol. 2019;29(5):542–543. From NLM. doi: 10.1684/ejd.2019.3626.
   PubMed Web of Science ®Google Scholar
• Carnicle JM, Hendricks AJ, Shi VY. Reactivation of alopecia areata after dupilumab therapy for atopic dermatitis. Dermatitis. 2021;32(1s):e80–e82. From NLM. doi: 10.1097/der.0000000000000512.
   PubMed Web of Science ®Google Scholar
• Gallo R, Trave I, Parodi A. Massive acute alopecia of the scalp in a patient treated with dupilumab. Acta Derm Venereol. 2020;100(13):adv00191. From NLM. doi: 10.2340/00015555-3549.
   PubMedGoogle Scholar
• Ständer S, Trense Y, Thaçi D, et al. Alopecia areata development in atopic dermatitis patients treated with dupilumab. J Eur Acad Dermatol Venereol. 2020;34(10):e612–e613. From NLM. doi: 10.1111/jdv.16493.
   PubMed Web of Science ®Google Scholar
• Maiolini VM, Sousa NA, Marsillac PF, et al. Alopecia areata-like and psoriasis after dupilumab use for atopic dermatitis. An Bras Dermatol. 2021;96(5):634–636. From NLM. doi: 10.1016/j.abd.2021.03.005.
   PubMed Web of Science ®Google Scholar
• Beaziz J, Bouaziz JD, Jachiet M, et al. Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature. Ann Dermatol Venereol. 2021;148(3):198–201. From NLM. doi: 10.1016/j.annder.2021.02.003.
   PubMed Web of Science ®Google Scholar
• Yamane S, Nakagawa Y, Inui S, et al. Development of alopecia areata-like reactions in a patient treated with dupilumab. Allergol Int. 2022;71(3):420–422. From NLM. doi: 10.1016/j.alit.2022.02.006.
   PubMed Web of Science ®Google Scholar
• Kulkarni M, Rohan CA, Morris D, et al. Resolution of dupilumab-associated alopecia areata with dosage modification. JAAD Case Rep. 2022;22:85–88. From NLM. doi: 10.1016/j.jdcr.2022.01.034.
   PubMedGoogle Scholar
• Jin P, Wei L, Zhang Q, et al. Dupilumab for alopecia areata treatment: a double-edged sword? J Cosmet Dermatol. 2022;21(11):5546–5548. From NLM. doi: 10.1111/jocd.15136.
   PubMed Web of Science ®Google Scholar